CClinicalTrials.gg
CompletedNCT03544970Updated Dec 19, 2018

An Audit of the Posterior Fossa Characterization in Open Spina Bifida Based on Tertiary Center Experience

An observational study in Fetal Anomaly, Spinal Dysraphism and Chiari Malformation Type 2, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Open to female participants. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
316
Sex
Female
01

Study summary

Brain stem and posterior fossa measurements in spina bifida aperta fetuses to compare them with normal population. Additionally, Describe the difference between pre- and postoperative findings.

Read the detailed description

Spina bifida aperta (SBA), often referred to as myelomeningocele (MMC) or myeloschisis, is a devastating yet non-lethal congenital malformation with complex physical and neurodevelopmental sequelae. Its prevalence is approximately 4.9 per 10,000 live births in Europe and 3.17 in the United States. SBA results in motor and sensory deficits, their extension being defined by the upper level of the anatomical defect. These range, as the level increases, from bladder, bowel and sexual dysfunction, to involvement of the lower and even upper extremities, and secondary orthopaedic disabilities. Despite improvements in prevention, diagnosis, and postnatal management, SBA remains a major source of morbidity and mortality throughout the world. Children with SBA almost invariably have an associated Chiari II hindbrain malformation (CM II) and ventriculomegaly. The Chiari II malformation is characterized by posterior fossa (PF) and brain stem abnormalities, with downward displacement and compression of the cerebellum and brain stem.

Geerdink demonstrated that morphometric measures reliably quantify the morphological distortions of Chiari II malformation on postnatal MR images. These included downward herniation of the cerebellum, displacement of pons, medulla and fourth ventricle, medullary kinking, abnormal fourth ventricle, tentorium and mesencephalic tectum. The mamillopontine distance (MPD) and the cerebellar width were the most sensitive and specific determinant of Chiari II. Some foetuses with SBA have ventriculomegaly and its degree is believed to be predictive for the need of postnatal shunting.

In 2011, the Management of Myelomeningocele Study (MOMS) demonstrated the benefit of in utero repair of MMC as the need for ventricular shunting at 12 months was reduced and motor outcome at 30 months improved. Fetuses with the suspicion of SBA should be assessed comprehensively to counsel parents about the expected outcome and whether they would be candidates for fetal surgery. In this assessment, fetal MR has a crucial role to characterize the extent of brain abnormalities, the level of the lesion, and to rule out additional anomalies in fetuses with SBA. For fetal surgery eligibility, the presence of CM II on MR is a necessary finding. Many measurements have been proposed to describe the typical PF changes in fetuses with SBA, yet the reproducibility of these has rarely been studied. These include the transverse cerebellar diameter (TCD), the transverse diameter of the posterior fossa (TDPF), the midsagittal PF area, the level of cerebellar herniation and the clivus-supraocciput angle (CSA). These parameters have also been shown to change after in utero repair of SBA in small series and at different time points after fetal surgery, yet no study has consistently reported early postoperative assessment in utero.

The aims of this study were threefold: (1) to assess the reproducibility of measurements of the brain stem and PF that have been suggested to be representative on postnatal 8,9 and prenatal MR imaging (2) apply those parameters that were shown to be reproducible, to discriminate fetuses with SBA from gestational age matched fetuses with a normal PF; (3) and document early changes in these measurements one week after fetal surgery.

02

Conditions studied

  • Fetal Anomaly
  • Spinal Dysraphism
  • Chiari Malformation Type 2

Keywords

  • fetal MRI
  • Posterior fossa
03

In context

Spinal Dysraphism

152 studies on the registry are indexed under Spinal Dysraphism; 37 are open to participants now.

This study's enrollment of 316 is above the median of 91 across 54 observational studies indexed under Spinal Dysraphism.

Browse Spinal Dysraphism studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Fetuses with spina bifida aperta with an additiona lsubgroup of matched pairs with pre- and postoperative imaging

Inclusion criteria

  • patients were those having fetal MR examination for additional assessment because of the prenatal diagnosis of SBA on ultrasound.
  • appropriate gestational age - matched controls. The latter were fetuses assessed for other congenital anomalies, which do not affect the central nervous system (CNS) or were scanned for suspected CNS abnormalities with normal prenatal US, fetal MR and normal postnatal evaluation

Exclusion criteria

Exclusion Criteria:

  • twin pregnancy, syndromal pathology, fetal hydrops or anhydramnios.
  • poor image quality
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
316 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. (1) assess the reliability of brain stem and posterior fossa measurements and compare the reliable ones with a normal populations (2) and between paired pre- and postsurgical fetuses

    Biometric variables include the transverse cerebellar diameter (TCD), Transverse diameter of the fossa posterior (TDPF), the midsagittal PF area. The ventricular width will be measured in the coronal plane according to Garel and in case of asymmetry the largest value will be taken into account. Mammilopontine distande (MPD), the level of kinking of the brain stem, medullary length, tentorial length and width of the cisterna magna will be measured. The width of the foramen magnum is defined as the distance between opisthion to the basion. Tonsillar level (TL) will be measured by drawing a perpendicular line from the foramen magnum to the lowest cerebellar portion. In the presence of cerebellar herniation the deepest portion will be used. The cerebellopontine angle will also be measured. These are all metric data and will be reported in mm. To adjust for normal changes according to gestational age, there will be a correction based on an observed/expeted ratio for the parameters.

    Time frame: Examinations from 2011 - 2016

07

Study locations

1 site
  • University Hospitals Leuven
    Leuven, 3000, Belgium
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03544970
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Responsible party
Sponsor
First posted
Jun 4, 2018
Start date
Apr 1, 2017
Primary completion
Oct 26, 2017
Completion
Oct 31, 2018
Last update
Dec 19, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion